Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock